SEDANA MEDICAL AB Financials Sedana Medical AB
Equities
SEDANA
SE0015988373
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.65 SEK | +9.14% |
|
+44.00% | -10.84% |
| Apr. 25 | Transcript : Sedana Medical AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Sedana Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,088 | 7,905 | 9,740 | 1,858 | 2,301 | 2,051 | - | - |
| Enterprise Value (EV) 1 | 2,623 | 7,529 | 8,904 | 1,250 | 2,069 | 1,828 | 1,957 | 1,978 |
| P/E ratio | -194 x | -288 x | -158 x | -25.3 x | -38.6 x | -25.8 x | -47.5 x | 413 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 43.1 x | 55.7 x | 61.2 x | 15.1 x | 15 x | 10.9 x | 8.56 x | 5.36 x |
| EV / Revenue | 36.6 x | 53 x | 55.9 x | 10.2 x | 13.4 x | 9.74 x | 8.17 x | 5.17 x |
| EV / EBITDA | -202 x | -538 x | -178 x | -15 x | -50.5 x | -79.8 x | -84.4 x | 53 x |
| EV / FCF | - | -81.4 x | -58.8 x | -4.94 x | -10 x | -8.27 x | -26.6 x | -180 x |
| FCF Yield | - | -1.23% | -1.7% | -20.3% | -10% | -12.1% | -3.76% | -0.56% |
| Price to Book | 5.42 x | 14.3 x | 8.84 x | 1.8 x | - | - | - | - |
| Nbr of stocks (in thousands) | 90,946 | 92,187 | 99,337 | 99,337 | 99,337 | 99,337 | - | - |
| Reference price 2 | 33.95 | 85.75 | 98.05 | 18.70 | 23.16 | 20.65 | 20.65 | 20.65 |
| Announcement Date | 3/5/20 | 2/25/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 71.65 | 142 | 159.2 | 122.9 | 153.9 | 187.6 | 239.7 | 382.8 |
| EBITDA 1 | -12.98 | -14 | -50.09 | -83.14 | -40.97 | -22.9 | -23.2 | 37.35 |
| EBIT 1 | -17.17 | -21 | -61.49 | -105.9 | -63.55 | -46.15 | -47.4 | - |
| Operating Margin | -23.96% | -14.79% | -38.64% | -86.18% | -41.3% | -24.59% | -19.77% | - |
| Earnings before Tax (EBT) 1 | -15.2 | -24.1 | -57.37 | -72.93 | -59.02 | -89 | -45.5 | 16 |
| Net income | -14.61 | -27.14 | -57.97 | -73.51 | -59.61 | - | -42 | 4 |
| Net margin | -20.39% | -19.11% | -36.42% | -59.83% | -38.74% | - | -17.52% | 1.05% |
| EPS 2 | -0.1750 | -0.2975 | -0.6200 | -0.7400 | -0.6000 | -0.8000 | -0.4350 | 0.0500 |
| Free Cash Flow 1 | - | -92.46 | -151.5 | -253.2 | -206.9 | -221 | -73.5 | -11 |
| FCF margin | - | -65.12% | -95.18% | -206.09% | -134.5% | -117.77% | -30.66% | -2.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/25/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 46.36 | 33.65 | 26.87 | 26.5 | 35.8 | 37.78 | 37.29 | 34.26 | 44.54 | 48.82 | 45.55 | 43.65 | 49.55 | 53.5 |
| EBITDA 1 | -13.49 | -16.44 | -23.94 | -25.1 | -17.64 | -10.66 | -10.71 | -12.55 | -7.051 | - | -6.2 | -4.6 | -8.45 | -5.4 |
| EBIT 1 | -18.68 | -22.06 | -29.81 | -30.8 | -23.25 | -16.3 | -16.31 | -18.09 | -12.85 | -6.566 | -13 | -17 | -16 | - |
| Operating Margin | -40.3% | -65.55% | -110.95% | -116.23% | -64.92% | -43.14% | -43.74% | -52.81% | -28.85% | -13.45% | -28.54% | -38.95% | -32.29% | - |
| Earnings before Tax (EBT) 1 | -17.11 | -18.83 | -11 | -7.333 | -35.77 | -16.01 | 1.619 | -6.739 | -37.89 | 20.82 | -13 | -16 | -17 | - |
| Net income 1 | -16.79 | -18.97 | -11.15 | -7.4 | -35.94 | -16.12 | 1.424 | -6.843 | -38.07 | 20.66 | -13 | -16 | -17 | - |
| Net margin | -36.22% | -56.38% | -41.49% | -27.92% | -100.38% | -42.67% | 3.82% | -19.98% | -85.47% | 42.31% | -28.54% | -36.66% | -34.31% | - |
| EPS 2 | -0.1800 | -0.1900 | -0.1100 | -0.0800 | -0.3600 | -0.1600 | 0.0100 | -0.0700 | -0.3800 | 0.2100 | -0.1300 | -0.1600 | -0.1700 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | 12.00 | 12.00 | 12.00 | - |
| Announcement Date | 2/17/22 | 4/28/22 | 7/21/22 | 10/25/22 | 2/16/23 | 4/27/23 | 7/21/23 | 10/26/23 | 2/15/24 | 4/25/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 465 | 376 | 836 | 608 | 231 | 223 | 94 | 73 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -92.5 | -151 | -253 | -207 | -221 | -73.5 | -11 |
| ROE (net income / shareholders' equity) | - | - | - | -6.9% | -5.76% | -9% | -3% | 0.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - | - |
| Book Value Per Share | 6.260 | 5.980 | 11.10 | 10.40 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | 84.6 | 110 | 0.74 | 0.52 | - | 55 | 30 |
| Capex / Sales | - | 59.59% | 69.28% | 0.6% | 0.33% | - | 22.95% | 7.84% |
| Announcement Date | 3/5/20 | 2/25/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
20.65
SEK
Average target price
35.5
SEK
Spread / Average Target
+71.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.84% | 187M | |
| -59.36% | 82M |
- Stock Market
- Equities
- SEDANA Stock
- Financials Sedana Medical AB
